It shouldn't be that easy. I was literally thinking of buying CSGN as the header "Suisse Government provides liquidity to Credit Suisse". I own Deutsche Bank (again), Credit Suisse, First Republic Bank (California) all from very low prices.
Guys, I am the 'despised' professional trader/investor. I am the idiot who shorted Tesla at $350+ and closed it out at $106 (SeekAlpha forums and REddit). Built a Nivdia position years ago for <$140 and sold it at $300+ late 2021, rebought it at $130 and is now (to my surprise) shorting it at $250. Bought APT on IPO, sold out too early at $45, but shorted at $120+. Again, called an idiot relentlessly on Hot Copper for shorting ZIP at $12+ and now (even more so) for buying it at $0.50. The only place I have really been an idiot in investment in the last few years, like many of you, is listening too much to one or two of the executives at OCC prior to COVID (oh and in all painful honesty, not buying XJO put options when I watched as COVID unfolded and the mkts continued up against my short futures - would have been set for life and not on here typing this crap).
OCC is screaming good value, even heavily allowing for an indolent board and inconsistent executive branch. We all know its potential. If you understand finance, you know that alas the OCC Board and executive management not untypical of the ASX small mkt cap end of biotech. They pay themselves and award themselves far too much for their output, but the Bio HOrizons deal was a rabbit out of the hat and removed the need for the dreaded capital raise and very probably allows them to get to positive cash flow (the holy grail of start ups, and prerequisite for the big boy money) and get their more lucrative applications of CelGro to market (and eventually ATI and perhaps even ACI - Vericel have taken their $55M investment and killed it with ACI in their MACI application and OCC will likely just hold on to coat tails there). Biotech takes time, but bar the BH deal, I agree, these lot even underperform the average low performance bar other Aussie biotech executives set. There are so many poor examples alas.
Cybertechbio and I disagree on the merits of a US listing (me on cost practicalities) but I absolutely concur with him that if this thing traded in the US it would be five, six, seven times the value it is. I am on a few US biotechs with far, far inferior promise trading far, far higher in mkt cap.
It will take time, and still only be relatively light vs the big boys, but a few years $30,40 even $50 million a quarter on Striate and Remplir possible. ATI revenues could be $2 million or could be $200 mill a quarter. Who knows? The stock is a pure call option when it comes to ATI that I admit I have dropped my delta a little on it (delta's definition for those not familiar with options, includes the probability of being 'in the money') and will require a partnership to be a big returner in the medium time frame. Your frustration in OCC's management will struggle to compare to mine as a patient who had ATI treatment in 2014 and sees these idiots still barely have progressed its commercialisation that should have been a game changer globally by now.
To illustrate the importance of OCC's IP however, I know someone who is sat on the Aussie rights to a very good European rival synthetic product to the LARS ligament (and CelGro Rope). He literally is waiting for a big buyer (and is of modest means in the mean time). If no one comes for it, he literally will block any use in Australia. I can only keep reiterating, Paul and Professor Zheng sold some ACI rights for $55 million to Vericel. Vericel now trades at $1.5 billion predominantly on successful commercialisation therein (I sold some Vericel shares yesterday morning, somewhat reluctantly, to buy more OCC).
).
(20min delay)